Wim G. Goettsch - Search Results

Year	Number of Results
2003	1
2004	4
2005	2
2006	5
2007	3
2011	2
2012	1
2013	1
2014	3
2015	1
2017	1
2018	2
2019	3
2020	6
2021	11
2022	12
2023	3
2024	5

1

High cost oncology drugs without proof of added benefit are burdening health systems.

Brinkhuis F, Goettsch WG, Mantel-Teeuwisse AK, Bloem LT. Brinkhuis F, et al. Among authors: goettsch wg. BMJ. 2024 Feb 29;384:q511. doi: 10.1136/bmj.q511. BMJ. 2024. PMID: 38423553 No abstract available.

2

Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study.

Brinkhuis F, Goettsch WG, Mantel-Teeuwisse AK, Bloem LT. Brinkhuis F, et al. Among authors: goettsch wg. BMJ. 2024 Feb 28;384:e077391. doi: 10.1136/bmj-2023-077391. BMJ. 2024. PMID: 38418086 Free PMC article.

3

Tools for assessing quality of studies investigating health interventions using real-world data: a literature review and content analysis.

Jiu L, Hartog M, Wang J, Vreman RA, Klungel OH, Mantel-Teeuwisse AK, Goettsch WG. Jiu L, et al. Among authors: goettsch wg. BMJ Open. 2024 Feb 13;14(2):e075173. doi: 10.1136/bmjopen-2023-075173. BMJ Open. 2024. PMID: 38355183 Free PMC article.

4

A literature review of quality assessment and applicability to HTA of risk prediction models of coronary heart disease in patients with diabetes.

Jiu L, Wang J, Javier Somolinos-Simón F, Tapia-Galisteo J, García-Sáez G, Hernando M, Li X, Vreman RA, Mantel-Teeuwisse AK, Goettsch WG. Jiu L, et al. Among authors: goettsch wg. Diabetes Res Clin Pract. 2024 Mar;209:111574. doi: 10.1016/j.diabres.2024.111574. Epub 2024 Feb 10. Diabetes Res Clin Pract. 2024. PMID: 38346592 Free article. Review.

5

Disease severity-based subgrouping of type 2 diabetes does not parallel differences in quality of life: the Maastricht Study.

Werkman NCC, García-Sáez G, Nielen JTH, Tapia-Galisteo J, Somolinos-Simón FJ, Hernando ME, Wang J, Jiu L, Goettsch WG, van der Kallen CJH, Koster A, Schalkwijk CG, de Vries H, de Vries NK, Eussen SJPM, Driessen JHM, Stehouwer CDA. Werkman NCC, et al. Among authors: goettsch wg. Diabetologia. 2024 Apr;67(4):690-702. doi: 10.1007/s00125-023-06082-4. Epub 2024 Jan 11. Diabetologia. 2024. PMID: 38206363 Free PMC article.

6

Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement.

Wang T, McAuslane N, Goettsch WG, Leufkens HGM, De Bruin ML. Wang T, et al. Among authors: goettsch wg. Int J Technol Assess Health Care. 2023 Apr 11;39(1):e20. doi: 10.1017/S0266462323000144. Int J Technol Assess Health Care. 2023. PMID: 37039100

7

Synergy between health technology assessments and clinical guidelines for multiple sclerosis.

Hogervorst MA, Vreman RA, Zawada A, Zielińska M, Dawoud DM, de Jong BA, Mantel-Teeuwisse AK, Goettsch WG. Hogervorst MA, et al. Among authors: goettsch wg. Clin Transl Sci. 2023 May;16(5):835-849. doi: 10.1111/cts.13492. Epub 2023 Mar 1. Clin Transl Sci. 2023. PMID: 36855929 Free PMC article.

8

When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs.

Callenbach MHE, Vreman RA, Mantel-Teeuwisse AK, Goettsch WG. Callenbach MHE, et al. Among authors: goettsch wg. Int J Environ Res Public Health. 2022 Dec 26;20(1):340. doi: 10.3390/ijerph20010340. Int J Environ Res Public Health. 2022. PMID: 36612665 Free PMC article.

9

Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlook.

Callenbach MHE, Ádám L, Vreman RA, Németh B, Kaló Z, Goettsch WG. Callenbach MHE, et al. Among authors: goettsch wg. Drug Discov Today. 2023 Jan;28(1):103433. doi: 10.1016/j.drudis.2022.103433. Epub 2022 Nov 11. Drug Discov Today. 2023. PMID: 36372328 Free article.

10

Bridging health technology assessment and healthcare quality improvement using international consortium of health outcomes measurement standard sets.

Kalf RRJ, Zuidgeest M, Delnoij DMJ, Bouvy ML, Goettsch WG. Kalf RRJ, et al. Among authors: goettsch wg. Int J Technol Assess Health Care. 2021 Dec 21;38(1):e6. doi: 10.1017/S0266462321000520. Int J Technol Assess Health Care. 2021. PMID: 36317685

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

59 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year